Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition Academic Article uri icon

Overview

MeSH Major

  • Elafin
  • PTEN Phosphohydrolase
  • Poly(ADP-ribose) Polymerases
  • Prostatic Neoplasms
  • Tumor Suppressor Protein p53

abstract

  • The paucity of therapeutic options in advanced prostate cancer displays an urgent need for the preclinical assessment of novel therapeutic strategies. We identified differential therapeutic vulnerabilities that emerge upon the loss of both PTEN and p53, and observed that combined inhibition of PARP and PI3K provides increased efficacy in hormone-insensitive advanced prostate cancer.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4125493

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-13-0230

PubMed ID

  • 24866151

Additional Document Info

start page

  • 896

end page

  • 904

volume

  • 4

number

  • 8